Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab

Sean Warsch, Peter J. Hosein, Michele I. Morris, Uygar Teomete, Ronald Benveniste, Jennifer R. Chapman, Izidore S. Lossos

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

A 66-year-old female developed progressive multifocal leukoencephalopathy (PML) 17 months after treatment with bendamustine and rituximab chemoimmunotherapy. During her evaluation for PML, she was found to have a CD4 count of 176 cells/μL (reference range 492-1740). The patient demonstrated spontaneous recovery of symptoms that occurred in parallel with recovery of the CD4 counts. While PML is associated with rituximab therapy, the timing and patients' clinical course are atypical, raising the possibility of a previously unreported association with bendamustine therapy.

Original languageEnglish
Pages (from-to)274-278
Number of pages5
JournalInternational Journal of Hematology
Volume96
Issue number2
DOIs
StatePublished - Aug 2012
Externally publishedYes

Keywords

  • Bendamustine
  • Mantle cell lymphoma
  • Progressive multifocal leukoencephalopathy
  • Rituximab

Fingerprint

Dive into the research topics of 'Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab'. Together they form a unique fingerprint.

Cite this